=GTx Inc. (GTXI) : phase 2 trial failure

GTx Inc. (GTXI) dropped 92% in Friday trade after the company said that enobosarm, its therapy intended for post-menopausal women with stress urinary incontinence, did not meet the primary endpoint in a phase 2 clinical trial. The double-blind and placebo-controlled trial had enrolled nearly 500 women. Enobosarm is the company's main product candidate, which it has been developing in stress urinary incontinence as well as breast cancer. GTx is also developing a preclinical candidate for prostate cancer. Company shares have surged nearly 26% to $23.29 over the last three months.